Physician profile
Harmeet Singh
NPI 1245271402
$87,000.47
in general payments reported to CMS, 2019-2025
51 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,178 · 2020: $2,248 · 2021: $1,997 · 2022: $29K · 2023: $19K · 2024: $9,451 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $8,978 · Consulting Fee: $1,525 · Travel and Lodging: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,012.50 |
| Food and Beverage | $8,977.85 |
| Consulting Fee | $1,525.00 |
| Travel and Lodging | $392.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $64,389.25 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $8,413.78 | 2019-2025 | Ajovy, Austedo, Austedo Xr |
| Pfizer INC. | $1,993.77 | 2021-2025 | |
| Livanova USA, INC. | $1,310.87 | 2020 | |
| Lundbeck LLC | $1,259.92 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $1,069.69 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Novartis Pharmaceuticals Corporation | $951.02 | 2019-2025 | |
| Ucb, INC. | $849.40 | 2019-2025 | Briviact |
| Biogen, INC. | $778.40 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Allergan, INC. | $682.52 | 2019-2022 | |
| Amgen INC. | $451.71 | 2019-2025 | Uplizna, Aimovig |
| Sumitomo Pharma America, INC. | $408.53 | 2023-2024 | Aptiom |
| Eisai INC. | $371.86 | 2021-2025 | |
| Emd Serono, INC. | $238.34 | 2019-2023 | Mavenclad |
| Boston Scientific Corporation | $237.13 | 2019 |
Show all 50 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.